This forecast includes Fanapt, HETLIOZ, and PONVORY but excludes ... and imsidolimab could impact future product launches and revenue contributions. Vanda Pharmaceuticals emphasized its strategic ...
Vanda Pharmaceuticals Inc ... formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to ...
Vanda Pharmaceuticals Inc. (NASDAQ ... VNDA's current product lineup is anchored by Fanapt, PONVORY, and HETLIOZ. Fanapt, in particular, has shown promising signs in its adoption for Bipolar ...
Hosted on MSN1mon
Is it a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?Vanda Pharmaceuticals Inc. VNDA generates revenues from the sale of its three commercial products, Fanapt, Hetlioz and Ponvory. Fanapt is approved in the United States for two indications ...
Fanapt Net Product Sales (Full Year 2024 ... future growth in their psychiatry portfolio. Vanda Pharmaceuticals Inc (NASDAQ:VNDA) launched PONVORY for the treatment of multiple sclerosis ...
Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...
“We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan ... as the anti-inflammatory portfolio that includes Ponvory ® for multiple sclerosis, psoriasis and ulcerative ...
Vanda Pharmaceuticals (VNDA ... “We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan disorders, as well as explore the potential of this IL-36 signal regulator ...
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt ® net product sales of $ ... 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback